SOURCE: Barrier Therapeutics, Inc.

September 19, 2006 16:20 ET

Barrier Therapeutics to Present at the UBS Global Life Sciences Conference

PRINCETON, NJ -- (MARKET WIRE) -- September 19, 2006 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Geert Cauwenbergh, Ph.D., Chief Executive Officer, and Al Altomari, Chief Operating Officer, are scheduled to present to the investment community at the UBS Global Life Sciences Conference.

The conference will be held at the Grand Hyatt New York in New York on September 25-28, 2006. Dr. Cauwenbergh and Mr. Altomari are scheduled to present on Thursday, September 28th, at 11:00 am Eastern Daylight Time.

The presentation will be available live via a webcast that can be accessed through Barrier Therapeutics' corporate website at:

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution. Barrier has other product candidates in various stages of clinical development for the treatment of onychomycosis, psoriasis, acne, and fungal infections. The Company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada.

Contact Information

  • Contact:

    Barrier Therapeutics, Inc.
    Anne M. VanLent

    Noonan Russo
    Diane Perry